科倫博泰生物-B(06990.HK)年度收入15.4億元 同比增長91.6%
格隆匯3月25日丨科倫博泰生物-B(06990.HK)公吿,集團截至2023年12月31日止年度的收入為人民幣1,540.5百萬元,較截至2022年12月31日止年度的人民幣803.9百萬元增長91.6%。該增加乃主要由於來自根據與默沙東訂立的開發多達七項用於治療癌症的臨牀前ADC資產的許可及合作協定的收入。
於報吿期間的虧損由截至2022年12月31日止年度的人民幣616.1百萬元減少6.8%至截至2023年12月31日止年度的人民幣574.1百萬元。
集團截至2023年12月31日止年度的研發開支為人民幣1,030.97百萬元,較截至2022年12月31日止年度的人民幣845.98百萬元增加21.9%。該增加主要由於:(i)試驗與測試開支增加;(ii)員工成本增加;以及(iii)其他研發開支增加,如與公司研發活動有關的差旅開支、公用事業及交通開支。該等增加主要是由於集團對持續研發項目的投資增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.